Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Getting back down towards the Tasty Zone.
$TSOI last SS
Haha I hope I am this frickin cool at retirement
You too man better days coming here
Lol. I here you brother. I can't remember what I had for breakfast:) Cheers! Pier
Sorry, I'm retired, and forgot it wasn't Friday today. Things happed today that made it seemed like it was Friday. You just fired me up a little for another day of trading.
Isn't the market open tomorrow? -Pier.
Have a happy long weekend, and a really great 4th everyone.
'Pandemic babies' with no immunity are ending up in intensive care across Australia with respiratory illnesses
https://www.dailymail.co.uk/news/article-10958689/Covid-19-Australia-Pandemic-babies-no-immunity-viruses-ending-ICU.html
Updated: 02:23 EDT, 28 June 2022
Rising number of 'pandemic babies' with no immunity admitted to intensive care
Children presenting with 'co-infections' with Covid and other respiratory illness
RSV - respiratory syncytial virus - kills 120,000 young children each year globally
NSW cases have exploded from 355 a week just three weeks ago to 3775 a week
There is no vaccine for RSV but it has almost identical symptoms to flu and Covid
A concerning number of 'pandemic babies' with no immunity to respiratory viruses are ending up seriously ill in ICU.
Doctors have revealed children born during the Covid-19 pandemic are requiring intensive care 'from encountering viruses they haven't come across before', such as influenza, RSV and Covid.
The children had been born and raised when there were virtually no other viruses circulating in Australia, other than Covid-19.
The Children's Hospital at Westmead infectious diseases paediatrician Dr Philip Britton said an analysis of ICU admissions across shows babies are testing positive for influenza and Covid at the same time.
'Over the last month or so, we have seen four times the admissions to hospital for flu in children as for Covid,' Dr Britton told The Daily Telegraph.
Dr Britton said five per cent of the children presenting with co-infections were being admitted to ICU, a statistic he described as 'very concerning'.
About half of the children had no pre-existing health conditions, with the elevated number of admissions putting pressure on the hospital system.
Some of the 'pandemic babies' are presenting with inflammation of the chest, brain and heart caused by influenza, Covid, and RSV.
RSV - respiratory syncytial virus - is a major cause of lung infections in children and can lead to pneumonia or bronchiolitis, which is particularly dangerous in young infants.
Severe cases can kill babies and toddlers, whose tiny airways have not yet fully formed and who struggle to cope with the infection.
'Among that group who are previously well … It's not just a chest infection, some of these children can be impacted with the flu affecting the heart and the brain,' Dr Britton told The Daily Telegraph.
A warning was sounded about RSV three weeks ago when there were just 355 cases a week in NSW, but three weeks later that has rocketed up to 3,775 in a week.
Around a fifth of those developed the potentially lethal bronchiolitis, with 40 per cent of them ending up in hospital.
Infectious disease researcher Dr John-Sebastian Eden said the triple whammy of RSV, flu and Covid was packing out the emergency department of Sydney's Westmead Children's Hospital.
'There is a widespread three-way outbreak occurring,' he told Daily Mail Australia.
International borders opening up has seen flu come back and new strains of RSV.
'With Covid layered up on top, these are three main viruses which will lead to hospitalisation.'
During Covid, RSV continued to spread and split into two separate strains in the east and west of the country in the wake of Western Australia's prolonged isolation.
Researchers were shocked by the sudden rise of the disease in the first year of lockdowns, fuelled by keeping childcare centres open despite Covid restrictions.
'It was something we had never seen before,' said Dr Eden. 'Even in lockdown there was a lot of effort to keep childcare open.
'You only need a small amount of virus to build up a chain of transmission.'
The disease subsided in 2021, but has now bounced back with the current outbreak.
Dr Eden believes cases in NSW have yet to reach their peak, but is now braced for the outbreak to spread nationwide.
He expects the disease to spread across the southern half of the country at similar levels in the coming weeks.
'What happens is where you have an outbreak in NSW and we've got all those people travelling to other states from there, it then feeds outbreaks in other parts,' he said.
The disease subsided in 2021, but has now bounced back with the current outbreak.
HERE'S WHAT YOU NEED TO KNOW ABOUT RSV
RSV is normally a winter disease but Covid lockdowns saw an unexpected huge surge in summer cases last year.
Symptoms include a runny nose, cough, reduced feeding and fever. Complications include wheezing and difficulty breathing, which can develop into pneumonia.
Like Covid, it can be transferred by sneezing and coughing, but unlike Covid, young children are particularly affected by it.
'Most children will recover without needing specialist care in hospital, and children with mild infection can be treated with rest at home,' paediatrician Daniel Yeoh wrote in The Conversation.
'It’s the major cause of lung infections in children, commonly causing bronchiolitis.
'Severe cases occasionally lead to death, predominantly in very young infants.
Almost all children have had an RSV infection by the age of two, but infants in their first year of life are more likely to experience severe infections requiring hospitalisation, because their airways are smaller. Babies have also not built up immunity to RSV from previous years.
Dr Yeoh added: 'Treatment for RSV is focused on helping children with their breathing (for example, giving them oxygen) and feeding (for example, administering fluids through a drip).'
There is no vaccine for RSV but several are under development.
It’s a penny stock you know damn well the sec don’t give 2 shits. Got any proof the trials have started? Or is it pending financing.
Sec doesn’t care about pennies. You already know this.
Then tell us how come the SEC hasn't halted TSOI for publicly disseminating the fact that they received said funding.
And while you're at it feel free to edumuncate us blithering fools how come Biorasi hasn't issued a public statement disavowing their multi-nation phase III human clinical trials of TSOI's Jadicell hmmmmmmmmmmmmmmmmmm
$TSOI
Nobody said that nor did they imply this. I personally don’t believe they have funding. So that’s my belief and you can choose to have yours. Carry on.
Yes Biorasi, the FDA and the SEC all in cahoots with TSOI, CEO Dixon and the entire TSOI scientific advisory board to pull the wool over penny players eyes weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
Do your own due *yawn*
And I’m kidding in case your wondering. Just a lot of unknowns. Financing being the biggest shadow that we just got a take his word for....like EUA
hahhaa yep buddy! Hilarious that any serious OTC player would ever take the time to attempt to knock private placement funding that resulted in phase III human clinical trials being initiated.
Just imagine if CEO Dixon utilized in any typical OTC financing instrument other than a PPM, which all experienced penny playing vets know is the friendliest form of OTC financing instrument out there:)
Other than a press release do you have any proof.
Yes that it's, Biorasi is doing a multi-nation phase III human clinical trial on JadiCell for free by golly gee, said as facetiously as possible lmfao!!!
Quick summary of TSOI's foundational pipeline for anyone curious>>>
-61+JadiCell patents
-5 IND’s
-1 Phase III Asset, Trial ongoing
-Exclusive rights/Lung
-COPD IND
-Fortune 500 CRO/Biorasi
-12 RTT Treatments
-JadiCell/CTE/TBI
-Exclusive Rights/CTE/TBI
-IND# issued
-FDA first in class ID/CTE/Living
-3 RTT Treatments
-NO reverse splits
-StemVacs-V iPSC
-Allogen Biologics
-BRS-001
-Breast, leukemia, glioma
-stemvacs.com/
-CampbellCell/Schizophrenia
-Campbell Neurosciences
-Campbell Score/Suicidal Ideation
-Opioid Addiction ImmThrpy
-JadiCell/MSC/Exosomes
-TSOI-576/ Bispecific Antibody
-ApoptoCyte Procedure
-QuadraMune p
-NanoStilbene
-Projuvenol
-NanoCannabidiol
-NanoPlus
-DermalStilbene
-NuBrainer
-Properties in Idaho/15 acres
-2.55B O/S
-+400% increased sales year over year
Wow great summary, thanks for copying it over here morgan!
Morning doog, let's have a great TSOI day
copied from another board, thanks Traders Trader:
(61)+JadiCell patents
(5) IND’s
(1) Phase III Asset, Trial ongoing
-Exclusive rights/Lung
-COPD IND
-Fortune 500 CRO/Biorasi
-(12) RTT Treatments
JadiCell/CTE/TBI
-Exclusive Rights/CTE/TBI
-IND# issued
-FDA first in class ID/CTE/Living
-(3) RTT Treatments
NO reverse splits
StemVacs-V iPSC
-Allogen Biologics
-BRS-001
-Breast, leukemia, glioma
stemvacs.com/?page_id=153
-CampbellCell/Schizophrenia
Campbell Neurosciences
-Campbell Score/Suicidal Ideation
-Opioid Addiction ImmThrpy
JadiCell/MSC/Exosomes
TSOI-576/ Bispecific Antibody
ApoptoCyte Procedure
2.55b OS
400% increased sales yr/yr
-QuadraMune
-NanoStilbene
-Projuvenol
-NanoCannabidiol
-NanoPlus
-DermalStilbene
-NuBrainer
(3) Properties in Idaho/15 acres
You know what they say about assumptions....
Agreed JMC, they're buildin' it, and the world will soon be comin' cheers:)
My assumption is it involves massive dilution. That’s my personal opinion and I hope I am wrong. Seeing as we have not heard a damn peep from tsoi about the recent conference I’m guessing there was just nothing to it. I mean not a peep.
I wasn’t wrong about EUA. I hope to god I’m not right again.
probably so the unfriendly cant harass the investor. I find it to be good business. The short and distort folks are squirming
My question was why couldn’t he divulge who the funding was from when he announced it. Strange. I know he said it would be in the 10K but to why not an ounce who it was when it happened versus the 10 K announcement then that makes sense to me
I honestly don’t believe Tim has financing. Period. Like EUA he will drag it out and keep investors on the hook just to let them down 6 months down the road. I mean that’s a pure fact when it comes to EUA.
Still patiently waiting for the Big TSOI news a comin soon doog
Yes, just patiently waiting now De302, thanks for checking in!
Wow ! Kinda quiet here lately.. Everyone feeling ok ? been here for several years and with invest and just kinda eaves drop from time to time... GLTA
Our time is gonna come, yes it is:)
Good article Doog, Thanks,
Long-COVID Lung Disease: Researchers Characterize 3 Phenotypes
Virginia A. Schad, PharmD, RPh
May 5, 2022
Doctor examining patients lungs, back, chest exam
Morphological analysis of lung tissue can offers insight into pathogenic mechanisms of post-COVID pulmonary sequelae and thereby guide clinical management.
Post-COVID lung disease includes 3 different subtypes or subgroups that potentially require separate and different management, according to a study published in the European Respiratory Journal.
Consequences of prolonged multi-organ symptoms and complications from COVID-19 infection are a growing health concern. Residual organ damage post-COVID-19 range from self-limited abnormalities to major lung diseases. Histological evaluation of lung tissue may reveal peculiar morpho-phenotypical changes which may help aid clinicians in understanding of pathogenic mechanisms and in providing appropriate therapy, the researchers noted.
In the current study, researchers examined the morphologic and immuno-molecular features of transbronchial lung cryobiopsies performed in patients with persistent lung disease after recovery from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. From January through March 2021, investigators conducted a comparative, prospective, observational study of adult patients referred to multiple centers for suspected pulmonary sequelae after COVID-19. All patients had recovered from COVID-19-related pneumonia at least 30 days prior, although none had been intubated, and had persistent lung involvement on high-resolution computed tomography scans and persistent respiratory and/or systemic symptoms. Most patients reported fatigue and low grade fever, with some reporting joint and muscle pain and depression.
Of the 164 referred patients, investigators conducted extensive analysis of 10 patients with parenchymal lung disease (extent >5%) who underwent lung biopsy. The researchers found that the histological pattern was not homogeneous among the patients; they noted 3 different “case clusters” characterized by specific clinical and radiological features. Cluster 1 (“chronic fibrosing”; n=2) was characterized by post-infection progression of pre-existing interstitial pneumonias, cluster 2 (“acute/subacute injury”; n=5) was characterized by different types and grades of lung injury ranging from organizing pneumonia and fibrosing nonspecific interstitial pneumonia to diffuse alveolar damage, and cluster 3 (“vascular changes”; n=3) was characterized by diffuse vascular increase, dilatation, and distortion of capillaries and venules within otherwise normal parenchyma. In particular, clusters 2 and 3 were characterized by immunophenotypical changes similar to those observed in early/mild COVID-19 pneumonias.
To date, this study appears to be the first correlating histological/immunohistochemical patterns with clinical and radiological pictures of patients with post-COVID lung disease. The researchers concluded that a multidisciplinary evaluation of patients with suspected long-COVID lung disease is needed to potentially characterize their phenotype and thereby provide insight into the most appropriate therapeutic interventions for managing a given patient.
This study was limited by its small sample size, short time frame, and the lack of baseline pulmonary patient data.
Reference
Ravaglia C, Doglioni C, Chilosi M, et al. Clinical, radiological, and pathological findings in patients with persistent lung disease following SARS-CoV-2 infection. Eur Respir J. Published online March 17, 2022. doi:10.1183/13993003.02411-2021
https://www.pulmonologyadvisor.com/home/topics/lung-infection/long-covid-lung-disease-phenotypes/
Shhhhhhhh quiet period before the shit storm
Next Compelling Event?
Can someone please state exactly what compelling event we’re waiting on for this stock to break out (e.g., approval, buy-out/merger, etc.)? Thanks.
Not sure why Walmart can’t deliver quadroon in a timely matter. I went to order it today from Walmart and it said on there delivery July 6 which is about 11 days off so I went to Amazon ordered it there and it’s delivered in two days
TimGDixon » Tue Jun 21, 2022 2:35 am
I know there is a lot of pent up anticipation from Bio but as several people have stated; we won't have any updates for a bit. Venvalo has a bunch of followup to do which will include NDA's for sure so I give you all fair warning that you may hear silence for a bit.
https://forum.therapeuticsolutionsint.com/viewtopic.php?p=5198&hilit=silence#p5198
To answer your question it was typo I was traveling and trying to use voice text.
I’m sure anxious for some kind of news to come out of the bio conference in San Diego.
$TSOIthe Iron Triangle of the American Medical Association, Big Pharma, and the giant insurance companies have a financial interest in maintaining the status quo of “cut and burn” cancer treatments, massively expensive cancer drugs, and ignoring other safer alternatives.
Good article, thanks.
$TSOIHow do we achieve a world without #cancer? Insightful article by Dr. James D. Veltmeyer, $TSOI Chief Medical Officer.
#CancerResearch #Immunotherapy #CellTherapy #CancerVaccines
https://www.lassennews.com/a-world-without-cancer/
Hey just a question, that's the second time I've noticed you've used a notation saying that I'm working on something, or I'm doing something. Is there a connection, or just an error typing?
Johnny where I was coming from on the manipulation is we have 60 some IP’s and patents and we can’t get above 2 1/2 cents. Just like you said any buying coming in is offset by someone selling or dumping shares. At this stage in the game with all white we have build up on IP‘s a common or normal person should be selling taken a chance that this thing could jump any day or when something great happens.
As far as the funding by a private investor or investors I have no idea who it is. It possibly could be Tom or maybe some doctors from the advisory board doctor or doctors I mean who knows I don’t know why the big secret that can’t be said puzzles me that we’ll just have to wait to see when the announcements made
I was hoping that enrollment has started and I’m sure they’re probably certain things I’m working on it to get started be nice to have an update on it from our CEO
United States Patent Application 20220193127 June 23, 2022
Kind Code A1 Ichim; Thomas ; et al.
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=16&f=G&l=50&co1=AND&d=PG01&s1=dixon&OS=dixon&RS=dixon
thanks gint1
There isn’t anything on enrollment or much at all regarding proof of phase 3. I believe it’s happening but would love to see what’s going on as well as who this mystery financier is.
Followers
|
528
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
64379
|
Created
|
10/04/08
|
Type
|
Free
|
Moderators BigBadWolf johnnytrader33 JMC$ Yooperman Hogwarts |
Preclinical Data Suggests QuadraMune™ Prevents Stress-Induced Suppression of Neurogenesis More Effectively than Prozac
OCEANSIDE, Calif., Dec. 9, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today new data suggesting the possibility that QuadraMune™ may mediate neuroprotective activity through preserving the ability of regenerative brain cells to proliferate subsequent to psychological stress.
The experiments, which involved exposing mice to established stressors, demonstrated that specific areas of the brain associated with production of new brain cells are damaged by stress. In agreement with previously published research, administration of fluoxetine (Prozac™) protected the brain from stress-induced damage. Surprisingly, QuadraMune™ administration appeared superior to Prozac™ at stimulating proliferation of new brain cells.
"QuadraMune™ which is currently in a clinical trial for prevention of COVD-191, has also been demonstrated to possess anti-inflammatory activity in other clinical trials, suppressing cytokines such as IL-62, which are known to be involved in depression3 and suicide4" said Kalina O'Connor, Director of Campbell Neurosciences and co-inventor on the patent. "Given major depressive disorder causes a significant risk for suicide, we are highly interested in exploring the use of QuadraMune™ for preventing suicide."
"Although much enthusiasm has been generated over the planned distribution of the COVID vaccine, at present little is being done to address mental health issues that are being exacerbated by the current pandemic" said Dr. James Veltmeyer, co-inventor of the patent, and Chief Medical Officer of the Company. "If current results are reproducible, the possibility that a nutraceutical would concurrently boost immunity while preserving mental health is highly enticing."
"It has not escaped us that COVID-19 is associated with increased inflammatory cytokines in the blood of patients, cytokines that also predispose to depression" said Famela Ramos, Vice President of Business Development for the Company. "It may be that the recent increase in suicides and suicide attempts is related biologically to activities of the coronavirus. It will be interesting to examine whether QuadraMune™ may modify putative negative mental effects of the virus."
"An estimated 17.3 million adults in the United States had at least one major depressive episode. This number represented 7.1% of all U.S. adults" stated Timothy Dixon, President and CEO of the Company. "We believe the Mission of our Company is not just providing a return on investment to our shareholders, but also increasing the quality of life for Americans. We are extremely pleased to report this unexpected finding with significant potential implications to advancing non-toxic means of helping patients with this terrible condition."
1 QuadraMune(TM) for Prevention of COVID-19 - Full Text View - ClinicalTrials.gov
2 Therapeutic Solutions International Announces Positive Preclinical and Clinical Evaluation of Nutritional Supplement QuadraMune™, Designed to Protect Against COVID-19 | BioSpace
3 Ting et al. Role of Interleukin-6 in Depressive Disorder. Int J Mol Sci. 2020 Mar 22;21(6):2194.
4 O'Donovan et al. Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress Anxiety. 2013 Apr;30(4):307-14.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |